{"entity":{"id":"boston-scientific","kind":"company","name":"Boston Scientific","aka":[],"tldr":"Medical device giant whose TheraSphere glass microspheres deliver yttrium-90 radioembolisation in liver cancer.","summary":"Boston Scientific, based in Marlborough, Massachusetts, and listed as BSX, is the medical device company whose TheraSphere glass microspheres deliver yttrium-90 radioembolisation in liver cancer. TheraSphere has held FDA approval for hepatocellular carcinoma since 2021, was studied in the EPOCH trial in colorectal liver metastases, which was positive for progression-free survival, and is being tested in combination with immunotherapy, and the company also sells drug-eluting embolic beads and other interventional oncology devices. Nuclide links it to hepatocellular carcinoma and colorectal cancer and to the radioembolisation and transarterial chemoembolisation technology records. Whether device-based liver-directed therapy keeps its role as systemic options improve is the open question. The technology pages carry the trial detail.","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/Boston_Scientific","links":[{"label":"Official website","url":"https://www.bostonscientific.com"}],"tags":[],"related":["y-90"],"indications":["hcc"],"sections":[],"technologies":["radioembolisation-tare"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05063565"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Marlborough, MA","country":"US","companyType":"devices","website":"https://www.bostonscientific.com","ticker":"BSX","investors":[],"funding":[]},"route":"/companies/boston-scientific/","neighbours":{"isotope":[{"id":"y-90","kind":"isotope","name":"Yttrium-90","route":"/isotopes/y-90/"}],"indication":[{"id":"hcc","kind":"indication","name":"Hepatocellular carcinoma","route":"/indications/hcc/"}],"technology":[{"id":"radioembolisation-tare","kind":"technology","name":"Radioembolisation (TARE / SIRT, yttrium-90)","route":"/technologies/radioembolisation-tare/"}],"trial":[{"id":"nct05063565","kind":"trial","name":"TheraSphere With Durvalumab and Tremelimumab for HCC","route":"/trials/nct05063565/"}],"drug":[{"id":"y-90-glass-microspheres","kind":"drug","name":"Yttrium-90 glass microspheres","route":"/drugs/y-90-glass-microspheres/"}],"company":[{"id":"bwxt-medical","kind":"company","name":"BWXT Medical","route":"/companies/bwxt-medical/"},{"id":"quirem-medical","kind":"company","name":"Quirem Medical","route":"/companies/quirem-medical/"}],"section":[{"id":"f-radioembolisation","kind":"section","name":"Radioembolisation","route":"/fronts/f-radioembolisation/"}],"pairing":[{"id":"tare-plus-durvalumab-hcc","kind":"pairing","name":"Radioembolisation (TARE) with durvalumab in hepatocellular carcinoma","route":"/pairings/tare-plus-durvalumab-hcc/"}]}}